US 11,897,830 B2
Crystal form and amorphous form of dezocine analogue hydrochloride
Yang Zhang, Shanghai (CN); Wentao Wu, Shaghai (CN); and Zhixiang Li, Shanghai (CN)
Assigned to SHANDONG DANHONG PHARMACEUTICAL CO., LTD., Shandong (CN)
Filed by Shandong Danhong Pharmaceutical Co., Ltd., Shandong (CN)
Filed on May 6, 2022, as Appl. No. 17/738,373.
Application 17/738,373 is a division of application No. 16/611,926, granted, now 11,339,119, previously published as PCT/CN2018/093721, filed on Jun. 29, 2018.
Claims priority of application No. 201710532702.8 (CN), filed on Jul. 3, 2017.
Prior Publication US 2022/0259140 A1, Aug. 18, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 219/26 (2006.01)
CPC C07C 219/26 (2013.01) [C07B 2200/13 (2013.01); C07C 2603/80 (2017.05)] 5 Claims
 
1. An amorphous form of a compound represented by formula (II),

OG Complex Work Unit Chemistry
wherein an X-ray powder diffraction spectrum of the amorphous form is shown in FIG. 1.